2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - New Orleans Theatre C
Technology and Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Diseases, Hemoglobinopathies, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

916 Prognostic utility of the international prognostic index and development of a novel risk score in diffuse large B-cell lymphoma (DLBCL) treated with bispecific antibody therapy

Elisa De Togni, MD, Jarrod Smith, MD2, Shakthi P. Bhaskar, MD3, Andrew P. Jallouk, MD, PhD4, Gulrayz Ahmed, MD5, Sairah Ahmed, MD6, Amy A. Ayers7, Steven Bair, MD8, Allison Marie Bock, MD9, Ayushi Chauhan, MD10, Jennifer L. Crombie, MD11, Alexey V. Danilov, MD, PhD12, Narendranath Epperla, MD, MS, FACP13, Lorenzo Falchi, MD14, Christopher R. Flowers Jr, MD, MS15, Sonia Godbole, MD16, Mehdi Hamadani, MD17, Alex Francisco Herrera, MD18, Matthew A. Lunning, DO, FACP19, Ajay Major, MD, MBA20, Reid W Merryman, MD21, Gilles Salles I, MD, PhD22, Yazeed Sawalha, MD23, Geoffrey Shouse, DO PhD24, Swetha Thiruvengadam, MD25, Vivek Patel, MD26
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Vanderbilt University Medical Center, Nashville, Tennessee, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 University of Colorado, Aurora, Colorado, United States
9 University of Utah Health Care, Salt Lake City, Utah, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 City of Hope, Duarte, California, United States
13 University of Utah Health Care, Salt Lake City, Utah, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Ohio State University, Columbus, Ohio, United States
17 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
18 City of Hope, Duarte, California, United States
19 University of Nebraska, Omaha, Nebraska, United States
20 University of Colorado, Aurora, Colorado, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Ohio State University, Columbus, Ohio, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States
26 Vanderbilt University Medical Center, Nashville, Tennessee, United States

Background: International Prognostic Index (IPI) prognosticates survival outcomes in patients (pts) with newly diagnosed DLBCL based on 5 risk-factors: age >60, stage III/IV, ECOG ≥2, elevated LDH, and >1 site of extranodal disease. However, it is unclear if IPI accurately risk stratifies these pts in the era of bispecific antibody (BsAb) therapy. Here we perform an exploratory regression multivariate analysis to investigate the utility of IPI and other variables in predicting survival outcomes in DLBCL pts receiving BsAb therapy.

Methods: This retrospective multicenter observational study included adults with biopsy-proven DLBCL treated with CD20×CD3 BsAb from 2022–2026 at 10 US CUBIC centers. Pts with calculable IPI at initiation of BsAb were included. PFS and OS were measured from first BsAb dose. Pts without an event were censored at last known alive. Survival was estimated using the Kaplan Meier method and associations with outcomes were evaluated using univariable and multivariable Cox regression. Variables associated with PFS and OS were incorporated into an equal weight prognostic score and assessed using Harrell’s C-index and bootstrap internal validation.

Results: We included 370 pts with median age of 70 years (range, 22–93) of whom 248 (67%) were male. Pts received BsAb with glofitamab (n=211, 57%), epcoritamab (n=142, 38%), or mosunetuzumab (n=17, 5%). Most pts 211 (57%) received single-agent BsAb, 131 (35%) received BsAb combined with systemic therapy, and 24 (6%) with radiation. Median follow-up was 13.6 months. At BsAb initiation, 307 pts (83%) had stage III/IV disease, 96 (26%) had ECOG ≥2, and 195 (53%) had >1 extranodal site. Median LDH was 282 U/L (IQR, 206–484), and 250 pts (68%) had elevated LDH. IPI scores at BsAb initiation were 0 in 2 pts (0.5%), 1 in 34 pts (9.2%), 2 in 88 (23.8%), 3 in 100 (27.0%), 4 in 104 (28.1%), and 5 in 42 (11.4%). Bulky disease ≥7 cm occurred in 72 pts (20%). High-grade B-cell lymphoma occurred in 59 pts (16%), and 115 (31%) transformed from an indolent lymphoma. Pts received a median of 3 prior lines of therapy (range, 1–16), and 249 (67%) were refractory within 6 months to prior line. Prior CAR-T therapy was administered to 177 pts (48%). Among 97 pts with CAR-T as the line immediately preceding BsAb, 12 (12%) initiated BsAb within 3 months of CAR-T initiation.

The objective response rate (ORR) was 54% (95% CI, 49%–59%). Complete response rate (CRR) was 34% (95% CI, 29%–39%). Median PFS was 3.8 months (95% CI, 3.5–4.9). Median OS was 10.4 months (95% CI, 8.5–12.4).

Increasing IPI was associated with inferior PFS (HR per point, 1.34; 95% CI, 1.20–1.50; P<0.001; C-index, 0.605) and OS (HR per point, 1.60; 95% CI, 1.41–1.83; P<0.001; C-index, 0.652). In an exploratory grouped analysis, median PFS was 8.1 months (95% CI, 5.1–19.2), 4.3 months (95% CI, 3.0–5.8), and 2.5 months (95% CI, 1.8–3.5) for IPI 0–2, 3, and 4–5 respectively (log-rank P<0.001). Corresponding median OS was 23.7 months (95% CI, 14.4–not reached), 12.0 months (95% CI, 7.1–21.2), and 5.4 months (95% CI, 4.1–7.5) respectively (log-rank P<0.001).

A novel 4-point prognostic score was developed by assigning 1 point each for ECOG ≥2, elevated LDH, >1 extranodal site, and refractory disease within 6 months to the immediately preceding line. The score was calculable in 357 pts. Pts were classified as low risk with 0–1 points (n=103, 28.9%), intermediate risk with 2 points (n=119, 33.3%), or high risk with 3–4 points (n=135, 37.8%). Median PFS was 18.2 months (95% CI, 6.9–23.7), 5.1 months (95% CI, 3.5–8.6), and 1.8 months (95% CI, 1.5–2.5) in the low, intermediate, and high-risk groups respectively (P<0.001). Median OS was 23.7 months (95% CI, 14.4–not reached), 16.1 months (95% CI, 8.5–24.8), and 4.9 months (95% CI, 3.2–6.1), respectively (P<0.001).

Each 1-point increase in the novel score was associated with inferior PFS (HR, 1.56; 95% CI, 1.38–1.75; P<0.001) and OS (HR, 1.72; 95% CI, 1.50–1.97; P<0.001). After bootstrap internal validation, the optimism-corrected C-index of the novel score was 0.653 for PFS, compared with 0.603 for IPI, and 0.679 for OS, compared with 0.651 for IPI.

Conclusion: In this retrospective analysis, we assess the utility of IPI and other variables in predicting PFS and OS in pts with DLBCL receiving BsAb. We propose a novel 4-point score that improves prognostication compared to IPI with superior discrimination ability. These findings require further external validation studies.

Elisa De Togni, MD: No relevant conflicts of interest to declare.